Buprenorphine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Buprenorphine: From Opioid Use Disorder to Acute Intermittent Porphyria
One-Sentence Summary
Buprenorphine is a partial μ-opioid receptor agonist and κ-opioid receptor antagonist used globally for treating opioid use disorder and moderate-to-severe pain, though it is not currently registered in Taiwan. The TxGNN model predicts it may have relevance for Acute Intermittent Porphyria (AIP) as the top-ranked new indication (score: 99.41%), with 0 clinical trials and 1 case report currently supporting this direction — the connection reflects a safety-profile association rather than a disease-modifying therapeutic claim.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Opioid Use Disorder / Pain Management (globally established; not registered in Taiwan) |
| Predicted New Indication | Acute Intermittent Porphyria |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L4 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the current Evidence Pack (Data Gap: DG002). Based on well-established global pharmacology, Buprenorphine is a partial agonist at the μ-opioid receptor (MOR), an antagonist at the κ-opioid receptor (KOR) and δ-opioid receptor, and a partial agonist at the nociceptin/orphanin FQ peptide receptor (NOP/ORL1). This unique receptor profile underpins its dual therapeutic role in opioid dependence management and analgesia.
The mechanistic rationale for the AIP prediction is safety-based rather than therapeutic. Buprenorphine exhibits low CYP1A2 and CYP2C9 induction activity, meaning it theoretically does not promote the accumulation of δ-aminolevulinic acid (δ-ALA) or other porphyrin precursors responsible for triggering acute porphyric crises. This places Buprenorphine among the preferred opioid analgesics for pain management in AIP patients who require perioperative or chronic pain control — a “porphyria-safe” classification recognized in anesthetic and metabolic disease guidelines.
It is important to distinguish this safety association from a disease-modifying treatment claim. The sole supporting publication (PMID 8301837, 1993) describes anesthetic management of an AIP patient using Buprenorphine during oncological surgery — it documents safe use in an AIP patient, not the use of Buprenorphine to treat AIP itself. The TxGNN knowledge graph appears to have captured this safety-adjacency relationship, but direct therapeutic repurposing of Buprenorphine for AIP as a primary indication has no current clinical or mechanistic basis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8301837 | 1993 | Case Report | Masui (Japanese Journal of Anesthesiology) | Perioperative anesthetic management of a 40-year-old female AIP patient undergoing ovarian tumor surgery; Buprenorphine was selected for its low porphyrinogenic risk. Describes safe use in an AIP patient, not treatment of AIP. |
Taiwan Market Authorization
No Taiwan (TFDA) regulatory licenses on record. Buprenorphine is not currently registered in Taiwan (market_status: 未上市).
Safety Considerations
Please refer to the relevant SmPC or prescribing information for safety data.
Important note: Taiwan-specific package insert (仿單) warnings and contraindications were not retrievable during this review (Data Gap: DG001 — severity: Blocking). This gap prevents formal S1 safety screening. Any clinical evaluation must be preceded by retrieval and review of the TFDA 仿單 or applicable regulatory safety documents.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction for Acute Intermittent Porphyria appears to capture Buprenorphine’s known porphyria-safe profile — its low CYP induction activity makes it a preferred opioid option for AIP patients requiring analgesia — rather than identifying a genuine disease-modifying therapeutic opportunity. With zero clinical trials and only a single 1993 case report documenting perioperative safety rather than AIP treatment, the evidence base cannot support progression to clinical investigation for this indication.
To proceed, the following is needed:
- Hypothesis clarification first: Define the research question — is the goal to evaluate Buprenorphine as a safe analgesic within AIP (already reasonable and supported by existing safety literature), or as a disease-modifying agent targeting heme biosynthesis or porphyrin pathway?
- If the former: A structured safety-in-AIP literature review would suffice; no new trials are indicated
- If the latter: Mechanistic studies establishing how opioid receptor modulation interacts with the heme biosynthesis pathway are needed before any clinical work — this hypothesis currently has no published basis
- DG001 remediation: Retrieve and review the TFDA 仿單 PDF for warnings, contraindications, and drug interactions (currently a blocking data gap)
- DG002 remediation: Query DrugBank API to confirm full MOA, receptor binding profile, and CYP interaction data
Reviewer note — Highest-evidence repurposing candidate in this pack: Among all 10 TxGNN-predicted indications evaluated, Schizophrenia (rank 8, L2) carries the strongest evidence base: 4 clinical trials including an actively recruiting Phase 2 RCT (NCT05778591, n=40, 2024–2026) directly testing low-dose Buprenorphine for schizophrenia negative symptoms (social motivation), plus 20 publications including a 1987 open-label clinical trial (PMID 3310672) and a 2020 meta-analysis of opioid antagonists in schizophrenia (PMID 32516800). If the objective is to identify the most actionable repurposing opportunity from this Evidence Pack, Schizophrenia should be elevated for priority review with a recommended decision of Research Question / Proceed with Guardrails.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.